A study has found that aficamten is associated with improvements across a range of clinical outcomes in patients with obstructive hypertrophic cardiomyopathy.

Rolling Submission of NDA for Aficamten Completed and Submitted to FDA in Q3 COMET-HF, Confirmatory Phase 3 Clinical Trial of ...

View the full release here: "We are honored to be recognized with the Prix Galien Award for Best Digital Health Solution," ...

Death is a daunting prospect for many, but after a lot of reflection and work on herself, Bella Salsberry feels at peace with the life she's been granted.

The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy ... and Sisunatovir for respiratory syncytical virus. Receive News & Ratings for ...

In a remarkable display of expertise and advanced cardiac care, KMC Hospital, Dr B R Ambedkar Circle successfully treated Fr Wolfgang Leonhard, a 65-year-old German national, who was rushed to the ...

Analyst Roanna Ruiz of Leerink Partners maintained a Buy rating on Cytokinetics (CYTK – Research Report), reducing the price target to ...

Analyst Mani Foroohar from Leerink Partners maintained a Buy rating on Tenaya Therapeutics (TNYA – Research Report) and keeping the price ...

As age increases, it becomes important for women to take special care of their health. According to health experts, after the age of 35, eve..|News Track ...

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the third quarter of 2024 and recent business highlights.

Rohit Bal has been suffering from a cardiac disease known as dilated cardiomyopathy for quite some time. It is a condition in ...